A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

Lydia Usha, Michael W. Sill, Kathleen M. Darcy, Doris M. Benbrook, Jean A. Hurteau, David P. Michelin, Robert S. Mannel, Parviz Hanjani, Koen De Geest, Andrew K. Godwin

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences